InMed Pharmaceuticals
About InMed Pharmaceuticals
InMed Pharmaceuticals is a Vancouver-based pharmaceutical company developing cannabinoid-based therapies and manufacturing technologies for rare cannabinoids. The company combines drug development with proprietary biosynthesis technology for producing pharmaceutical-grade cannabinoids at scale.
Key Facts
- 1Developing cannabinol (CBN) based therapies for dermatological and ophthalmic conditions
- 2Proprietary IntegraSyn platform for biosynthetic manufacturing of rare cannabinoids
- 3INM-755 is in clinical development for epidermolysis bullosa, a rare skin disease
- 4One of the few pharmaceutical companies focused on rare cannabinoids beyond THC and CBD
Frequently Asked Questions
What are rare cannabinoids?
Rare cannabinoids are compounds found in cannabis in very small quantities, such as cannabinol (CBN), cannabigerol (CBG), and others. InMed focuses on developing therapeutics from these lesser-known cannabinoids and uses biosynthesis to produce them at pharmaceutical scale.
What is the IntegraSyn platform?
IntegraSyn is InMed's proprietary biosynthesis manufacturing platform that can produce pharmaceutical-grade rare cannabinoids without growing cannabis plants, enabling more efficient and scalable production.
More Cannabis Companies in Vancouver
Products
- INM-755 (cannabinol cream for skin disease)
- INM-088 (cannabinol for glaucoma)
- IntegraSyn biosynthesis platform
Specialties
Company Details
- Type
- Medical & Pharma
- Location
- Vancouver, Canada
- Founded
- 2014
- Publicly Traded
- Yes
- Ticker
- NASDAQ:INM